Articles by Jordana Jampel
UGN-102 could become the first FDA-approved therapy for low-grade intermediate-risk non-muscle invasive bladder cancer.
Disease control was achieved in 84.6% of patients, 4.3% reached a complete response, 52% had partial response.
The primary endpoint of rPFS was maintained in both cohorts.
Better quality of life and higher optimism showed to alter the perception people with metastatic disease have about cure.
[⁸⁹Zr]Zr-girentuximab PET-CT ccRCC prognostic imaging has a favorable safety profile and is highly accurate.
Prognostic and predictive phenotypic biomarkers have been identified for rPFS and OS in de novo mCSPC.
PFS was improved with nivolumab plus cabozantinib.
In patients with pretreated UC, BL-B01D1 demonstrated manageable safety with encouraging antitumor activity.
Enfortumab vedotin plus pembrolizumab showed consistent PFS and OS benefit across all subgroups.
The AMBASSADOR study demonstrated a significant improvement in disease-free survival for pembrolizumab.
NLR can be a prognostic predictor of clinicopathology in UTUC, aiding risk stratification and management.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.